Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mersana Therapeutics Inc (NQ: MRSN )

2.958 -0.252 (-7.87%)
Streaming Delayed Price Updated: 12:20 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Mersana Therapeutics Inc

< Previous 1 2 3 4 5 Next >
Dow Surges Over 300 Points; Kroger Profit Beats Views
U.S. stocks traded higher midway through trading, with Dow Jones gaining more than 300 points on Thursday. The Dow traded up 0.98% to 34,313.85 while the NASDAQ rose 0.73% to 13,726.16. The S&P 500,... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023
Via Benzinga
US Stocks Open Higher; Retail Sales Rise In May
U.S. stocks traded higher this morning, with Dow Jones gaining around 180 points on Thursday. Following the market opening Thursday, the Dow traded up 0.53% to 34,159.59 while the NASDAQ rose 0.18% to... 
Via Benzinga
Mersana Therapeutics's Return On Capital Employed Insights
Via Benzinga
FDA Halts Mersana's Early-Stage Cancer Trial After Patient Death
Via Benzinga
Mersana Therapeutics's Return On Capital Employed Insights
Via Benzinga
Coinbase Is Falling, but a Nasdaq Biotech Stock Is Thursday's Big Loser
Markets gave back some ground after consideration of the Fed's latest interest rate decision. 
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Are Mersana Therapeutics Shares Nosediving Today
The FDA has issued a partial clinical hold pausing new patient enrollment in Mersana Therapeutics Inc's (NASDAQ: MRSN) UP-NEXT and UPGRADE-A, the company's ongoing clinical trials of UpRi in  
Via Benzinga
7 Stocks to Buy for 200% Returns This Year
These high return stock investments all have the potential to triple in 2023 based on Wall Street expectations. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
US Stocks Edge Higher; AMD Shares Tank Despite Upbeat Results
U.S. stocks traded up this morning, ahead of the Federal Reserve’s decision on an interest rate hike. Following the market opening Wednesday, the Dow traded up 0.05% to 33,700.93 while the NASDAQ rose... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023
Via Benzinga
With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Mersana Inks Cancer Therapy Development Deal With Merck Germany
Via Benzinga
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Recap: Mersana Therapeutics Q3 Earnings
Mersana Therapeutics (NASDAQ:MRSN) reported its Q3 earnings results on Monday, November 7, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Mersana Therapeutics... 
Via Benzinga
Myovant Sciences And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Why Nauticus Robotics Shares Are Trading Higher By 96%; Here Are 67 Biggest Movers From Yesterday
Gainers Chardan NexTech Acquisition 2 Corp. (NASDAQ: CNTQ) shares surged 102.6% to close at $21.54 on Wednesday. 
Via Benzinga
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
Via Benzinga
Mersana Shares Climb As FDA Grants Fast Track Status To Triple-Negative Breast Cancer Candidate
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics’ (NASDAQ: MRSN) lead candidate XMT-1660 for the treatment of adult patients with advanced or... 
Via Benzinga
Mersana Therapeutics's Return On Capital Employed Insights
Mersana Therapeutics (NASDAQ:MRSN) brought in sales totaling $4.28 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 10.5%, resulting in a loss of $52.22... 
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method. 
Via Benzinga
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session
Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD.... 
Via Benzinga
Why U.S. Stocks Are Trading Mixed; Labor Costs Increase Higher-Than-Expected In Q2
U.S. stocks traded mixed this morning, with the Nasdaq dropping around 90 points on Tuesday. 
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.